Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma
Status:
Active, not recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This Phase 3, 2-arm, randomized, active comparator-controlled, open-label, multicenter study
will compare the efficacy and health-related quality of life (HR-QoL) and assess the safety
of selinexor plus bortezomib (Velcade) plus low-dose dexamethasone (SVd) versus bortezomib
plus low-dose dexamethasone (Vd) in adult patients with RRMM who have received 1 to 3 prior
anti-multiple myeloma (MM) regimens. Crossover from the Vd Arm to a treatment that includes
selinexor (i.e., SVdX or SdX) will be allowed at the point of IRC-confirmed objective disease
progression per the IMWG criteria for patients in the Vd Arm.